Back to results
US 2010/0247537 A1Published application
Adjuvant combinations of nkt activator, cd40 agonist, and optional antigen, the use through inducing synergistic cellular immunity
AssigneeImmurx, Inc.
InventorsCory Ahonen, Randolph Noelle
Life of this patent
Estimating the term…
Abstract
Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (α-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided.
Claims33
An adjuvant combination which elicits a synergistic effect on T cell immunity comprising:
- (i) at least one agonist of CD40;
- (ii) at least one NKT activator;
- and
- (iii) optionally at least one desired antigen.
1 more element
Dependencies are inferred from the claim text.